Over the coming months, Citron Research will release a series of articles on Questcor (NASDAQ:QCOR) intended to shed light on probable issues of interest to the multi-pronged investigation underway by multiple regulatory agencies into numerous aspects of Questcor’s business strategy that political correct-speak would deem “legally challenged”. These articles will dig deeper into topics such as:
· The Chronic Disease Fund, and the role it plays in contributing to Questcor’s revenues
· Medicare billing (it is very dangerous to participate in a scheme to defraud the Federal Government)
· Insurance reimbursement coding for Acthar
Meanwhile, today’s question is whether Questcor’s Synacthen acquisition is anti-competitive. The points raised in Citron’s article last week are relevant to the FTC’s inquiry, demonstrating Questcor’s intent to suppress competition by acquiring Synacthen is exposed by their own sell-side analysts.
We are sure that Questcor will now try to posture to the FTC that Synacthen is a completely different drug, arguing that while it has similarities, it cannot be regarded as a replacement for HP Acthar Gel. This piece of evidence presented below is for the FTC, so shareholders please cover your eyes.
( Citron as always recommends downloading the PDF for local viewing, and clicking on the links.)